EMA Adopts a Positive Opinion for Dabrafenib for the Treatment of Glioma
It is intended in combination with trametinib for the treatment of low- and high-grade gliomas
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
NALIRIFOX Improves Survival Compared with Nab-paclitaxel Plus Gemcitabine in First-Line Treatment for Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Findings from the NAPOLI 3 study
A Robust, Durable Activity of Atezolizumab Observed in a Diverse Cohort of Patients with Advanced Alveolar Soft Part Sarcoma
Findings from the phase II study
No Clinically Meaningful Difference in Survival Between Nivolumab Plus Ipilimumab and Nivolumab Alone in Advanced Cancers Other Than Melanoma
Findings from a meta-analysis
Dabrafenib Plus Trametinib Improves Efficacy in Children and Adolescents with Relapsed/Refractory BRAF V600-mutated High-Grade Glioma
Findings from a phase II study
Sacituzumab Govitecan Demonstrates Overall Survival Benefit Over Chemotherapy in Patients with Pretreated, Endocrine-Resistant HR-positive, HER2-negative MBC
Findings from the TROPiCS-02 study
FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple Myeloma
Evidence for efficacy is based on results from the MonumenTAL-1 study
EMA Recommends Granting a Marketing Authorisation for Degarelix Accord
It is a generic of Firmagon which has been authorised in the EU since 2009
HER2-Low Expression Identified in Half of Solid Tumour Samples Tested for HER2 in a Large Cohort of Patients
Findings from the first study to report on HER2-low expression across multiple solid tumour types
Combination of Nivolumab and Ipilimumab Yields Better Outcomes Compared to Ipilimumab Alone in Patients with Advanced Melanoma and Primary Resistance to anti-PD1 or anti-PD-L1 Therapy
Findings from the S1616 study
Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but Promising for Salivary Duct Carcinomas
Findings from a phase II study
FDA Approves Melphalan As a Liver-Directed Treatment for Uveal Melanoma
Evidence for efficacy is based on the results from the FOCUS study